versameb Revenue and Competitors
Estimated Revenue & Valuation
- versameb's estimated annual revenue is currently $2.3M per year.
- versameb's estimated revenue per employee is $155,000
Employee Data
- versameb has 15 Employees.
- versameb grew their employee count by -29% last year.
versameb's People
| Name | Title | Email/Phone |
|---|
versameb Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is versameb?
Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business team. The company's focus is the development of novel RNA-based therapeutics. Versameb's proprietary VERSagile technology platform enables efficient development of functional mRNA molecules in multiple disease areas with high unmet medical need including dermatology, oncology and myology.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
versameb News
5 April 2022, Basel, Switzerland: Versameb AG (Versameb), focused on discovering and developing innovative RNA-based drugs,...
Enables Versameb to use Touchlight's proprietary doggybone DNA vector technology to support the development of novel mRNA-based therapeutics...
UK headquartered Touchlight has agreed a development and manufacturing pipeline agreement with Swiss company, Versameb.
Other Companies in Basel
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.2M | 15 | 0% | N/A |
#2 | $3.8M | 15 | -63% | N/A |
#3 | $2.3M | 16 | 78% | N/A |
#4 | $2.5M | 17 | 6% | N/A |
#5 | $3.6M | 18 | 0% | N/A |